Stay up to date

recent news & press releases

September 2, 2022

How oncRNA Technology Could Revolutionize Cancer Diagnostics

When it comes to diagnostic technology, the more options a clinician has the better, particularly for cancer. Exai Bio is developing liquid biopsy tests using non-coding RNA or oncRNA technology and AI to give clinicians a way to assess cancer with a simple blood test.

In a recent interview with CLP, Pat Arensdorf, our co-founder and chief executive officer, discussed how the company’s technology uses next generation sequencing (NGS) and AI, where oncRNA technology fits into the existing diagnostic continuum, and the benefits that oncRNA-based tests will contribute compared to other types of liquid biopsy test.

Read the whole article on CLP


want to learn more?
connect with us.

contact us
Close the cookie popup
Cookie Settings
By clicking "Accept All", you are agreeing to store cookies on your device to enhance your experience and help Exai's marketing.
Accept All
cookie settings